TRADING UPDATES: Plant Health Care announces GBP2.8 million fundraise
22nd Jun 2023 20:34
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday said its recent in vivo study targeting midkine-expressing cancers has shown "significant" success by its lead antibody programmes, which its CEO said "demonstrate the potential for a best-in-class medicine." Read More
Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Says recently completed in vitro studies for new messenger ribonucleic acid therapeutic show "statistically significant reduction" in proliferation and migration of breast and liver cancer. Study was part of Roquefort's new anti-cancer mRNA therapeutics platform focused on the Midkine growth target. The MDK mRNA programme was tested in validated in vitro cancer models to evaluate effect on growth and migration. Roquefort acknowledges that these are early results but says therapeutic shows potential to become first-in-class cancer treatment if they are replicated in clinical trials. It recently updated its filed patents to protect MDK mRNA programme compositions and methods. Programme now will move to in vivo studies. Read More
Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Share suspension lifted, following the publication of its results Monday. Read More
(Alliance News) - Roquefort Therapeutics PLC reported an increased loss for 2022 as costs rose in several areas, with the year including a successful acquisition, and said it expects to meet its targets for the current year. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Roquefort Therapeutics PLC - London-based biotechnology company focused on oncology market - Announces the successful development of a new novel platform of anti-cancer mRNA therapeutics. Says this is its fifth programme and the third in its Midkine family. The new platform consists of four mRNA pre-clinical therapeutics targeting Roquefort's Midkine target. Midkine is a human growth factor associated with cancer progression. Says it is now working towards demonstrating efficacy of the mRNA therapeutics in specific cancer targets, alongside the its existing oligonucleotide Midkine programme. Read More
Roquefort Therapeutics PLC - UK-based biotech company - Forms scientific advisory board to provide scientific guidance on strategy, as the company moves towards key pre-clinical milestones and clinical trials. Says SAB will initially comprise of Jo Martin, Trevor Jones and Armand Keating. Aims to use their drug development expertise to complete pre-clinical development to reach valuation milestones for licensing transactions or sale of a clinical programme. Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday said that it has signed an exclusive licence and royalty agreement with a diagnostics company, Randox Laboratories Ltd, in relation to its Midkine antibody portfolio. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Roquefort Therapeutics PLC on Monday was optimistic about its prospects for the new year, following a busy final quarter in 2022. Read More
Roquefort Therapeutics PLC - London-based biotech company - Will present results from its anti-cancer RNA pre-clinical study on Tuesday afternoon at European Society of Gene & Cell Therapy in Edinburgh. Results show that a splice switching RNA medicine can impair Midkine action. RNA turns genetic information into proteins. Midkine appears to enhance the proliferative features of cancer. Roquefort treatment reduces full length Midkine and generates a "non-functional shortened Midkine" by inducing a change in the Midkine mRNA. Read More
(Alliance News) - Roquefort Therapeutics PLC on Friday reported a widened pretax loss but maintained a strong cash balance. Read More
(Alliance News) - Roquefort Therapeutics PLC on Friday said it completed its acquisition of cancer-focused biotech firm Oncogeni Ltd for GBP5.5 million. Read More
Roquefort Therapeutics PLC - London-based biotechnology company - Says Midkine in vitro experiments completed with company's oligonucleotides reducing high MDK levels in cancer cells. "These positive results demonstrate the pre-clinical proof of principle in cancer for the antisense oligonucleotide drug development program and underpin the company's ability to progress to in vivo studies and clinical trials in due course targeting MDK in cancer," it says. On patent portfolio, has filed patents in Australia and UK to protect the composition of truncated MDK, mRNAs and antisense oligonucleotides. Adds it is working on publishing a prospectus, completing the acquisition of Oncogeni Ltd and GBP1.0 million fundraise. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Roquefort Therapeutics PLC - London-based biotechnology company - During the first half of 2022, the company says it has focused on progressing its collaboration with Murdoch University in Australia and reviewing its portfolio. Chair Stephen West says it has been a "very active start" to the year with "significant progress" made. Read More